GENE ONLINE|News &
Opinion
Blog

2021-07-26| Trials & Approvals

Albireo Gets Back-to-Back Approvals for Rare Liver Disease Drug

by Daniel Ojeda
Share To

On July 20th, Albireo announced that the FDA approved Bylvay to treat pruritus in all subtypes of progressive familial intrahepatic cholestasis (PFIC). This is a huge milestone for the company, as Bylvay is its first commercially available drug in the US. In addition, the approval came just one day after the European Commission approved Bylvay. As a result, the company’s stock is up 7.36% in the past 5 days.  

PFIC is a rare pediatric genetic disorder that causes progressive, life-threatening liver disease. Patients suffer from cholestasis, or bile accumulation in liver cells. Symptoms include itchiness, jaundice, poor weight gain, and slow growth. Within the first 10 years of life, PFIC leads to cirrhosis and liver failure. Bylvay is the first drug approved for the treatment of this disease.

“Treating children with PFIC can be difficult and frustrating given the current treatment options. Bylvay gives us a non-surgical option and will change how we treat PFIC,” said Richard Thompson, Professor of Molecular Hepatology at King’s College London.

 

Bylvay – The First of Albireo’s Many Candidates for Rare Liver Disease

Spun out of AstraZeneca and based in Boston, Albireo focuses on developing therapeutics for rare liver disease. They use novel bile acid modulators to treat rare pediatric and adult liver diseases. 

Their pipeline includes A3907, an inhibitor of apical sodium-dependent bile acid transporter (ASBT), which is currently in Phase 1 clinical trial to treat adult liver diseases. Additionally, their treatment for chronic constipation, Elobixibat, is approved in Japan and Thailand. Additionally, their lead compound Bylvay is also being tested in several Phase 3 clinical trials to treat Biliary Atresia, Alagille Syndrome, and other cholestatic diseases.   

Bylvay is a potent, once-daily, non-systemic ileal bile acid transport inhibitor (IBATi). Its efficacy was determined in the PEDFIC1 and PEDFIC2 Phase 3 clinical trials. In the randomized, double-blind, placebo-controlled, global multicenter PEDFIC1 study, Bylvay successfully reduced serum bile acid responses and itchiness (pruritus). PEDFIC2 showed the reduction in both markers was sustained in patients up to 48 weeks. Besides, Bylvay was well tolerated, with diarrhea being the most common adverse effect.

After the FDA nod, Albireo announced the packing and shipping of Bylvay within days. Sales promotions will begin immediately. Additional areas of focus are access and reimbursement and patient support. 

“Bylvay is the first-ever approval by the FDA of a drug developed for a pediatric cholestatic liver disease and provides a non-surgical treatment for patients living with the burden of PFIC,” said Ron Cooper, President, and CEO of Albireo. “We’re humbled by the children, families, and investigators whose commitment to our clinical trials will bring hope and treatment benefits for so many future patients.”

The approval of Bylvay is crucial for Albireo as it will bring more revenue, and the FDA issued a Rare Pediatric Disease Priority Review Voucher that the company plans to sell. As of June 30th, 2021, Albireo had between $183.3 million in cash and cash equivalents. The company anticipates that the sum will cover its operating expenses into 2023.

Related Article: Merck’s FDA approval for Pneumonia Vaccine Sets Up Collision Course with Pfizer

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
FDA Requests for a $7.2 Billion Budget in FY 2025 for Critical Health Initiatives
2024-03-12
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top